#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myelofibrosis HER2 mutant non-small cell lung cancer Synovial sarcoma Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Skin angiosarcoma Liposarcoma recurrent Myocarditis Acute on chronic liver failure Hyperinsulinaemic hypoglycaemia Cluster headache Fabry's disease Necrotising enterocolitis neonatal Follicle centre lymphoma follicular grade I II – III refractory Arteriovenous malformation Myotonic dystrophy More trials…

    Learn about Rare Diseases

    Arterial tortuosity syndrome – Life with Disease Pleural mesothelioma malignant – Diagnostics Lymphangiosarcoma – Trials in Disease Idiopathic pulmonary fibrosis – Treatment Myxofibrosarcoma – Trials in Disease Leiomyosarcoma – Basic Information Leiomyosarcoma metastatic Mastocytosis – Treatment Turner’s syndrome – Treatment Gastrointestinal stromal tumour – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Crd-4730 Candesartan Cilexetil CANNABINOL BUMETANIDE Bictegravir Prasugrel Hydrobromide Alpha-Tocopherol Pentoxifylline NORGESTIMATE Levocabastine Hydrochloride SKB410 Thiotepa Holcus Lanatus Pollen Extract Sodium Chloride CHLOROQUINE PHOSPHATE Azd4831 Radium Ra 223 Dichloride Piromelatine Oditrasertib Oritavancin More therapies…

    Learn about Your Condition

    Insulin resistance Respiratory distress Glioblastoma Thyroidectomy Bone marrow disorder Retinitis pigmentosa Ventricular tachycardia Intestinal infarction Frostbite Autoimmune disorder Menopause Gaucher's disease type I Cutibacterium acnes infection Oesophageal adenocarcinoma Albuminuria More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Mental Disorders

  • Study on the Effects of Psilocybin for Patients with Psychogenic Non-Epileptic Seizures (PNES)

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Psychogenic seizure
    • Seizure
    Investigated Drugs:
    • Psilocybine
    France

  • Study on RL-007 for Improving Cognitive Impairment in Schizophrenia Patients

    Not recruiting

    2 1
    Investigated Diseases:
    • Cognitive disorder
    • Schizophrenia
    Investigated Drugs:
    • (2R,3S)-2-Amino-3-Hydroxy-3-Pyridin-4-Yl-1-Pyrrolidin-1-Ylpropan-1-One (2R,3R)-2,3-Dihydroxybutanedioic Acid
    Bulgaria Czechia Poland

  • Study of KarXT (trospium chloride and xanomeline tartrate) in patients with inadequately controlled schizophrenia symptoms

    Not recruiting

    3 1
    Investigated Diseases:
    • Schizophrenia
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Bulgaria

  • Study on Long-Term Safety of Iclepertin for Patients with Schizophrenia Who Completed Previous Trials

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Schizophrenia
    Investigated Drugs:
    • Iclepertin
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Study on the Effects of NMRA-335140 for Adults with Major Depressive Disorder

    Not recruiting

    3 1
    Investigated Drugs:
    • 1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
    Bulgaria Czechia Finland France Germany Poland +1

  • Study on Long-term Safety and Effectiveness of NMRA-335140 for Patients with Major Depressive Disorder

    Not recruiting

    3 1 1
    Investigated Drugs:
    • 1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
    Bulgaria Czechia Finland France Germany Poland +1
Previous Page
1 … 35 36 37 38 39 40
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!